Cipla gets USFDA nod for pulmonary arterial hypertension drug

💻Jk News info 📰

NEW DELHI, Apr 30: Drug major Cipla Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Ambrisentan tablets, indicated for the treatment of pulmonary arterial hypertension.

Cipla’s Ambrisentan tablets 5 mg and 10 mg is AB-rated generic therapeutic equivalent version of Gilead Sciences Inc’s Letairis, the Mumbai-based company said in a BSE filing.

Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening, it added.

Cipla said the US sales of Letairis tablets USP stood at USD 943 million in 2018.

“The product is available for shipping immediately,” the company added.(PTI)

The post Cipla gets USFDA nod for pulmonary arterial hypertension drug appeared first on Jammu Kashmir Latest News | Tourism | Breaking News J&K.



News posted by jknewsinfo Click Here Download JK News info Android app from play store

Comments

Popular posts from this blog

Full list of ministers in the Narendra Modi Cabinet of 2019

Traffic to ply from Jammu to Srinagar for 2nd consecutive day, no vehicle from Kashmir

Oppn members stage walkout in LS over Unnao rape case issue